Innoxus

About Innoxus

Innosus is a medical device company established in February 2022 that develops and manufactures aesthetic equipment. The company's main office is located in Anyang-si, Gyeonggi-do, South Korea. In January 2026, Innosus successfully raised 14.2 billion KRW in a Series A funding round from investors including Altos Ventures, which will be used to accelerate global expansion and enhance research and development.

The founder and CEO is Jaeyong Shim, a medical doctor who graduated from Seoul National University College of Medicine after graduating first in his class from Seoul Science High School. With a background in clinical practice and previous entrepreneurial ventures in the diet and beauty sectors, Dr. Shim founded Innosus to address the limitations of existing aesthetic medical devices. The company's business model revolves around the manufacturing and sale of its innovative medical devices to clinics and hospitals worldwide. Revenue is generated through direct sales and export contracts.

Innosus's flagship product is 'Alltite', a skin lifting device that uniquely applies dielectric heating principles, a technology previously used in cancer treatment and rehabilitation, to aesthetic procedures. The core technology, Dermis Layer Target Dielectric heating system (DLTD), is an internationally patent-pending internal heating method that selectively heats the mid-to-lower dermis. This minimizes energy loss and significantly reduces pain and epidermal damage compared to conventional methods. Alltite is designed as a 'dual-target' lifting device, simultaneously affecting the dermis and the SMAS layer to provide both tightening and lifting effects in a single treatment. It also features a lower heat concentration in the subcutaneous fat layer, which substantially reduces the risk of side effects like 'volume loss' or facial depressions. Before its official launch in Korea, Innosus secured export contracts for over 300 units to countries such as Japan, Hong Kong, and Brazil, and has sold over 200 units within the first 10 months of its release.